Venous thromboembolism

CPD
By
AP Staff
-

References

  1. Therapeutic Guidelines. Cardiovascular chapter: Venous thromboembolism (VTE) treatment. 2024.
  2. Australian Commission on Safety and Quality in Health Care. Venous thromboembolism. In: Australian Commission on Safety and Quality in Health Care. 2018.
  3. Wells P, Anderson D. The diagnosis and treatment of venous thromboembolism. Hematology 2013;(1):457–63.
  4. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107(23 Suppl 1):I4–8.
  5. Moheimani F, Jackson DE. Venous thromboembolism: classification, risk factors, diagnosis, and management. ISRN Hematol 2011;(1):124610.
  6. Access Economics. The burden of venous thromboembolism in Australia: report by access economics Pty Limited for The Australia and New Zealand working party on the management and prevention of venous thromboembolism. 2008.
  7. Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I–9-I–16.
  8. Greenall R.Prevention, diagnosis and treatment of venous thromboembolism. Nurs Older People 2017;29(1):21–5.
  9. Lim W, Le Gal G, Bates SM, et al. American society of hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv 2018;2(22):3226–56.
  10. Australian Commission on Safety and Quality in Health Care. Venous thromboembolism prevention clinical care standard. 2020. At: www.safetyandquality.gov.au/standards/clinical-care-standards/venous-thromboembolism-prevention-clinical-care-standard
  11. Badireddy M, Mudipalli VR. Deep venous thrombosis prophylaxis; 2024. At: www.ncbi.nlm.nih.gov/books/NBK534865/#:~:text=DVT%20prophylaxis%20can%20be%20primary,the%20treatment%20of%20subclinical%20DVT
  12. Paul JD, Cifu AS. Prevention and management of venous thromboembolism. JAMA. 2019;322(16):1602–3. 
  13. Watson HG, Baglin TP. Guidelines on travel-related venous thrombosis. Br J Haematol 2011;152(1):31–4.
  14. Schreijer AJM, Cannegieter SC, Doggen CJM, et al. The effect of flight-related behaviour on the risk of venous thrombosis after air travel. British Journal of Haematology 2009;144(3):425–9.
  15. Clarke MJ, Broderick C, Hopewell S, et al. Compression stockings for preventing deep vein thrombosis in airline passengers. Cochrane Database of Systematic Reviews 2016. Issue 9.
  16. Philbrick JT, Shumate R, Siadaty MS, et al. Air travel and venous thromboembolism: a systematic review. J Gen Intern Med 2007;22(1):107–14.
  17. Gavish I, Brenner B. Air travel and the risk of thromboembolism. Intern Emerg Med 2011;6(2):113–6.
  18. Toff WD, Sugerman H, Eklöf BoG. Venous thrombosis related to air travel – reply. JAMA 2013;309(13):1347.
  19. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest.2016;149(2):315–52.
  20. Nicolaides AN, Fareed J, Spyropoulos AC, et al. Prevention and management of venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. Int Angiol 2024;43(1):1–222.
  21. Stevens H, Tran H, Gibbs H. Venous thromboembolism: current management. Aust Prescr 2019;42(4):123–6.
  22. Tran HA, Gibbs H, Merriman E, et al. New guidelines from the thrombosis and haemostasis society of Australia and New Zealand for the diagnosis and management of venous thromboembolism. Med J Aust 2019;210(5):227–35.
  23. Xarelto Product Information. eMIMSplus cloud 2024. At: www.emims.com.au/Australia/drug/search
  24. Eliquis Product Information. eMIMSplus cloud 2024. At: www.emims.com.au/Australia/drug/search
  25. Malik A, Ha NB, Barnes GD. Choice and duration of anticoagulation for venous thromboembolism. J Clin Med 2024;13(1):301.
  26. Khairani CD, Bejjani A, Piazza G, et al. Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials. J Am Coll Cardiol 2023;81(1):16–30.
  27. Martin K, Beyer‐Westendorf J, Davidson BL, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb and Haemost 2016;14(6):1308–13.
  28. Linnemann B, Beyer-Westendorf J, Espinola-Klein C, et al. Management of deep vein thrombosis: an update based on the revised AWMF S2k Guideline. Hamostaseologie 2024;44(2):97–110.
  29. Nieto JA, Bruscas MJ, Ruiz-Ribo D, et al. Acute venous thromboembolism in patients with recent major bleeding. The influence of the site of bleeding and the time elapsed on outcome. J Thromb Haemost 2006;4(11):2367–72.
  30. Klok FA, Huisman MV. How I assess and manage the risk of bleeding in patients treated for venous thromboembolism. Blood 2020;135(10):724–34.
  31. Khan F, Tritschler T, Kimpton M, et al. Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. Ann Intern Med 2021;174(10):1420–9.
  32. Horner T, Mahan CE. Venous thromboembolism: role of pharmacists and managed care considerations. Am J Manag Care 2017;23(20 Suppl):S391–8.
  33. Raskob GE, Angchaisuksiri P, Blanco AN, et al. Thrombosis: a major contributor to global disease burden. Semin Thromb Hemost 2014;40(7):724–35.